DARUNAVIR GLENMARK 400 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

darunavir glenmark 400 mg

pharamathen s.a. - grecia - darunavirum - compr. film. - 400mg - antivirale cu actiune directa inhibitori de proteaza

DARUNAVIR GLENMARK 800 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

darunavir glenmark 800 mg

pharamathen s.a. - grecia - darunavirum - compr. film. - 800mg - antivirale cu actiune directa inhibitori de proteaza

DARUNAVIR ACCORD 400 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

darunavir accord 400 mg

laboratori fundaciÓ dau - spania - darunavirum - compr. film. - 400mg - antivirale cu actiune directa inhibitori de proteaza

DARUNAVIR ACCORD 800 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

darunavir accord 800 mg

laboratori fundaciÓ dau - spania - darunavirum - compr. film. - 800mg - antivirale cu actiune directa inhibitori de proteaza

Comirnaty Uniunea Europeană - română - EMA (European Medicines Agency)

comirnaty

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaccinuri - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. utilizarea acestui vaccin ar trebui să fie în conformitate cu recomandările oficiale.

ABATIXENT 5 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

abatixent 5 mg

lek pharmaceuticals d.d. - slovenia - apixabanum - compr. film. - 5mg - antitrombotice antitrombotice

BOSENTAN TERAPIA 125 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

bosentan terapia 125 mg

sun pharmaceutical industries europe b.v. - olanda - bosentanum - compr. film. - 125mg - alte antihipertensive alte antihipertensive

KLACID 125 mg/5 ml România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

klacid 125 mg/5 ml

abbvie s.r.l. - italia - clarithromycinum - gran. pt. susp. orala - 125mg/5ml - macrolide, lincosamide si streptogramine macrolide

Firazyr Uniunea Europeană - română - EMA (European Medicines Agency)

firazyr

takeda pharmaceuticals international ag - icatibant - angioedem, ereditar - terapia cardiacă - firazyr este indicat pentru tratamentul simptomatic al atacurilor acute de angioedem ereditar (hae) la adulți (cu deficiență de inhibitor de c1-esterază).

Dengvaxia Uniunea Europeană - română - EMA (European Medicines Agency)

dengvaxia

sanofi pasteur - chimeric yellow fever dengue virus serotype 1 (live, attenuated), chimeric yellow fever dengue virus serotype 2 (live, attenuated), chimeric yellow fever dengue virus serotype 3 (live, attenuated), chimeric yellow fever dengue virus serotype 4 (live, attenuated) - dengue - vaccinuri - dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 6 to 45 years of age with test-confirmed previous dengue infection (see sections 4. 2, 4. 4 și 4. utilizarea de dengvaxia ar trebui să fie în conformitate cu recomandările oficiale.